# Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

> **NCT01832727** · PHASE1,PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 65 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Oprozomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01832727
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07-02
- **Primary completion:** 2019-06-25
- **Final completion:** 2019-06-25
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** Enrollment halted during phase 2 to reformulate the investigational product
- **Last updated:** 2020-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01832727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01832727, "Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01832727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*